Host susceptibility to non-tuberculous mycobacterial infections

The Lancet Infectious Diseases

Volumn 15, Issue 8, 2015, Pages 968-980

  Wu, Un In ^a,b   Holland, Steven M ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR GATA 2;

ATYPICAL MYCOBACTERIOSIS; AUTOSOMAL DOMINANT INHERITANCE; BACTERIAL IMMUNITY; CILIARY DYSKINESIA; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; FAMILY; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENOTYPE; GRANULOMA; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; INTRACELLULAR KILLING; LUNG DISEASE; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROPHYLAXIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; GENETIC PREDISPOSITION; GENETICS; MUTATION;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS;

EID: 84937735265     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00089-4     Document Type: Review

References (169)

1. Falkinham JO Ecology of nontuberculous mycobacteria-where do human infections come from?. Semin Respir Crit Care Med 2013, 34:95-102.
2. Maekawa K, Ito Y, Hirai T, et al. Environmental risk factors for pulmonary Mycobacterium avium-intracellulare complex disease. Chest 2011, 140:723-729.
3. Thomson R, Tolson C, Carter R, Coulter C, Huygens F, Hargreaves M Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J Clin Microbiol 2013, 51:3006-3011.
4. Saleeb P, Olivier KN Pulmonary nontuberculous mycobacterial disease: new insights into risk factors for susceptibility, epidemiology, and approaches to management in immunocompetent and immunocompromised patients. Curr Infect Dis Rep 2010, 12:198-203.
5. Kendall BA, Winthrop KL Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013, 34:87-94.
6. Weinstock DM, Feinstein MB, Sepkowitz KA, Jakubowski A High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 31:1015-1021.
7. Lai CC, Lee LN, Ding LW, Yu CJ, Hsueh PR, Yang PC Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J Infect 2006, 53:77-84.
8. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
9. Haverkamp MH, van Dissel JT, Holland SM Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling. Microbes Infect 2006, 8:1157-1166.
10. Lee WI, Huang JL, Yeh KW, et al. Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs). J Formos Med Assoc 2011, 110:750-758.
11. Rosenzweig SD, Holland SM Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev 2005, 203:38-47.
12. Casanova JL, Holland SM, Notarangelo LD Inborn errors of human JAKs and STATs. Immunity 2012, 36:515-528.
13. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119:753-766.
14. Salt BH, Niemela JE, Pandey R, et al. IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J Allergy Clin Immunol 2008, 121:976-982.
15. Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 2011, 12:213-221.
16. Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006, 18:347-361.
17. Holland SM Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity. Immunol Res 2007, 38:342-346.
18. Vinh DC, Masannat F, Dzioba RB, Galgiani JN, Holland SM Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-γ receptor 1 deficiency. Clin Infect Dis 2009, 49:e62-e65.
19. Vinh DC, Schwartz B, Hsu AP, et al. Interleukin-12 receptor beta1 deficiency predisposing to disseminated Coccidioidomycosis. Clin Infect Dis 2011, 52:e99-102.
20. Sampaio EP, Hsu AP, Pechacek J, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 2013, 131:1624-1634.
21. van de Vosse E, Hoeve MA, Ottenhoff TH Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 2004, 4:739-749.
22. Haller O, Kochs G, Weber F The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006, 344:119-130.
23. Bustamante J, Picard C, Boisson-Dupuis S, Abel L, Casanova JL Genetic lessons learned from X-linked Mendelian susceptibility to mycobacterial diseases. Ann N Y Acad Sci 2011, 1246:92-101.
24. Dorman SE, Uzel G, Roesler J, et al. Viral infections in interferon-γ receptor deficiency. J Pediatrics 1999, 135:640-643.
25. Zerbe CS, Holland SM Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency. Clin Infect Dis 2005, 41:e38-e41.
26. Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004, 364:2113-2121.
27. Kong XF, Ciancanelli M, Al-Hajjar S, et al. A novel form of human STAT1 deficiency impairing early but not late responses to interferons. Blood 2010, 116:5895-5906.
28. Chapgier A, Kong XF, Boisson-Dupuis S, et al. A partial form of recessive STAT1 deficiency in humans. J Clin Invest 2009, 119:1502-1514.
29. Roesler J, Kofink B, Wendisch J, et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNγR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 1999, 27:1368-1374.
30. Hirata O, Okada S, Tsumura M, et al. Heterozygosity for the Y701C STAT1 mutation in a multiplex kindred with multifocal osteomyelitis. Haematologica 2013, 98:1641-1649.
31. Dorman SE, Holland SM Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998, 101:2364-2369.
32. Bax HI, Freeman AF, Ding L, et al. Interferon α treatment of patients with impaired interferon gamma signaling. J Clin Immunol 2013, 33:991-1001.
33. Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-γ receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest 1997, 100:2658-2664.
34. Moncada-Velez M, Martinez-Barricarte R, Bogunovic D, et al. Partial IFN-γR2 deficiency is due to protein misfolding and can be rescued by inhibitors of glycosylation. Blood 2013, 122:2390-2401.
35. Jouanguy E, Dupuis S, Pallier A, et al. In a novel form of IFN-γ receptor 1 deficiency, cell surface receptors fail to bind IFN-γ. J Clin Invest 2000, 105:1429-1436.
36. Kong XF, Vogt G, Chapgier A, et al. A novel form of cell type-specific partial IFN-γR1 deficiency caused by a germ line mutation of the IFNGR1 initiation codon. Hum Mol Genet 2010, 19:434-444.
37. Sologuren I, Boisson-Dupuis S, Pestano J, et al. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet 2011, 20:1509-1523.
38. Remiszewski P, Roszkowska-Sliz B, Winek J, et al. Disseminated Mycobacterium avium infection in a 20-year-old female with partial recessive IFNγR1 deficiency. Respiration 2006, 73:375-378.
39. Doffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-γ receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection. J Infect Dis 2000, 181:379-384.
40. Kilic SS, van Wengen A, de Paus RA, et al. Severe disseminated mycobacterial infection in a boy with a novel mutation leading to IFN-γR2 deficiency. J Infect 2012, 65:568-572.
41. Kong XF, Vogt G, Itan Y, et al. Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease. Hum Mol Genet 2013, 22:769-781.
42. Rosenzweig SD, Dorman SE, Uzel G, et al. A novel mutation in IFN-γ receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol 2004, 173:4000-4008.
43. Prando C, Samarina A, Bustamante J, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 2013, 92:109-122.
44. Picard C, Fieschi C, Altare F, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002, 70:336-348.
45. de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010, 89:381-402.
46. Fieschi C, Dupuis S, Catherinot E, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor β1 deficiency: medical and immunological implications. J Exp Med 2003, 197:527-535.
47. Dorman SE, Holland SM Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000, 11:321-333.
48. Gruenberg DA, Anover-Sombke S, Gern JE, et al. Atypical presentation of IL-12 receptor β1 deficiency with pneumococcal sepsis and disseminated nontuberculous mycobacterial infection in a 19-month-old girl born to nonconsanguineous US residents. J Allergy Clin Immunol 2010, 125:264-265.
49. Boisson-Dupuis S, Kong XF, Okada S, et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol 2012, 24:364-378.
50. Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet 2003, 33:388-391.
51. Chapgier A, Wynn RF, Jouanguy E, et al. Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol 2006, 176:5078-5083.
52. Vairo D, Tassone L, Tabellini G, et al. Severe impairment of IFN-γ and IFN-α responses in cells of a patient with a novel STAT1 splicing mutation. Blood 2011, 118:1806-1817.
53. Averbuch D, Chapgier A, Boisson-Dupuis S, Casanova JL, Engelhard D The clinical spectrum of patients with deficiency of signal transducer and activator of transcription-1. Pediatr Infect Dis J 2011, 30:352-355.
54. Kristensen IA, Veirum JE, Moller BK, Christiansen M Novel STAT1 alleles in a patient with impaired resistance to mycobacteria. J Clin Immunol 2011, 31:265-271.
55. Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001, 293:300-303.
56. Chapgier A, Boisson-Dupuis S, Jouanguy E, et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet 2006, 2:e131.
57. Tsumura M, Okada S, Sakai H, et al. Dominant-negative STAT1 SH2 domain mutations in unrelated patients with Mendelian susceptibility to mycobacterial disease. Hum Mutat 2012, 33:1377-1387.
58. Sampaio EP, Bax HI, Hsu AP, et al. A novel STAT1 mutation associated with disseminated mycobacterial disease. J Clin Immunol 2012, 32:681-689.
59. Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011, 365:127-138.
60. Bogunovic D, Byun M, Durfee LA, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 2012, 337:1684-1688.
61. Uzel G The range of defects associated with nuclear factor kappaB essential modulator. Curr Opin Allergy Clin Immunol 2005, 5:513-518.
62. Hanson EP, Monaco-Shawver L, Solt LA, et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol 2008, 122:1169-1177. e16.
63. Niehues T, Reichenbach J, Neubert J, et al. Nuclear factor κB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol 2004, 114:1456-1462.
64. Filipe-Santos O, Bustamante J, Haverkamp MH, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med 2006, 203:1745-1759.
65. Ling KW, Ottersbach K, van Hamburg JP, et al. GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells. J Exp Med 2004, 200:871-882.
66. Kazenwadel J, Secker GA, Liu YJ, et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012, 119:1283-1291.
67. Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010, 115:1519-1529.
68. Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood 2013, 121:3830-3837.
69. Holme H, Hossain U, Kirwan M, Walne A, Vulliamy T, Dokal I Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J Haematol 2012, 158:242-248.
70. Browne SK Anticytokine autoantibody-associated immunodeficiency. Annual review of immunology. Annu Rev Immunol 2014, 32:635-657.
71. Chi CY, Chu CC, Liu JP, et al. Anti-IFN-γautoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood 2013, 121:1357-1366.
72. Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012, 367:725-734.
73. Hoflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 2004, 103:673-675.
74. Haverkamp MH, van de Vosse E, van Dissel JT Nontuberculous mycobacterial infections in children with inborn errors of the immune system. J Infect 2014, 68(suppl 1):S134-S150.
75. Roesler J, Horwitz ME, Picard C, et al. Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey. J Pediatrics 2004, 145:806-812.
76. Vogt G, Chapgier A, Yang K, et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 2005, 37:692-700.
77. Vogt G, Bustamante J, Chapgier A, et al. Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation. J Exp Med 2008, 205:1729-1737.
78. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999, 21:370-378.
79. Yancoski J, Sadat MA, Aksentijevich N, Bernasconi A, Holland SM, Rosenzweig SD A novel internalization motif regulates human IFN-γ R1 endocytosis. J Leukoc Biol 2012, 92:301-308.
80. Fleisher TA, Dorman SE, Anderson JA, Vail M, Brown MR, Holland SM Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol 1999, 90:425-430.
81. Fieschi C, Dupuis S, Picard C, Smith CI, Holland SM, Casanova JL High levels of interferon γ in the plasma of children with complete interferon γ receptor deficiency. Pediatrics 2001, 107:E48.
82. Al-Muhsen S, Casanova JL The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008, 122:1043-1051.
83. Altare F, Lammas D, Revy P, et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest 1998, 102:2035-2040.
84. Hirata O, Okada S, Tsumura M, et al. Heterozygosity for the Y701C STAT1 mutation in a multiplex kindred with multifocal osteomyelitis. Haematologica 2013, 98:1641-1649.
85. Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011, 208:1635-1648.
86. van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011, 365:54-61.
87. Uzel G, Sampaio EP, Lawrence MG, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type Immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 2013, 131:1611-1623.
88. Toth B, Mehes L, Tasko S, et al. Herpes in STAT1 gain-of-function mutation. Lancet 2012, 379:2500.
89. Marquis JF, Kapoustina O, Langlais D, et al. Interferon regulatory factor 8 regulates pathways for antigen presentation in myeloid cells and during tuberculosis. PLoS Genet 2011, 7:e1002097.
90. Salem S, Gros P Genetic determinants of susceptibility to Mycobacterial infections: IRF8, a new kid on the block. Adv Exp Med Biol 2013, 783:45-80.
91. Skaug B, Chen ZJ Emerging role of ISG15 in antiviral immunity. Cell 2010, 143:187-190.
92. Fan JB, Zhang DE ISG15 regulates IFN-γ immunity in human mycobacterial disease. Cell Res 2013, 23:173-175.
93. D'Cunha J, Knight E, Haas AL, Truitt RL, Borden EC Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 1996, 93:211-215.
94. Courtois G The NF-κB signaling pathway in human genetic diseases. Cell Mol Life Sci 2005, 62:1682-1691.
95. Puel A, Picard C, Ku CL, Smahi A, Casanova JL Inherited disorders of NF-κB-mediated immunity in man. Curr Opin Immunol 2004, 16:34-41.
96. Orange JS, Levy O, Brodeur SR, et al. Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J Allergy Clin Immunol 2004, 114:650-656.
97. Bustamante J Mendelian susceptibility to mycobacterial infections and defect in macrophages respiratory burst. Med Sci (Paris) 2011, 27:579-581. (in French).
98. Holland SM Chronic granulomatous disease. Hematol Oncol Clin North Am 2013, 27:89-99.
99. Bustamante J, Picard C, Fieschi C, et al. A novel X-linked recessive form of Mendelian susceptibility to mycobaterial disease. J Med Genet 2007, 44:e65.
100. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011, 118:2653-2655.
101. Bigley V, Collin M Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome. Haematologica 2011, 96:1081-1083.
102. Bigley V, Haniffa M, Doulatov S, et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med 2011, 208:227-234.
103. Mansour S, Connell F, Steward C, et al. Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases. Am J Med Genet A 2010, 152A:2287-2296.
104. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011, 43:929-931.
105. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011, 43:1012-1017.
106. Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics and immunity. Blood 2013, 123:809-821.
107. Camargo JF, Lobo SA, Hsu AP, Zerbe CS, Wormser GP, Holland SM MonoMAC syndrome in a patient with a GATA2 mutation: case report and review of the literature. Clin Infect Dis 2013, 57:697-699.
108. Ishida H, Imai K, Honma K, et al. GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia. Eur J Pediatr 2012, 171:1273-1276.
109. Browne SK, Holland SM Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis 2010, 10:875-885.
110. Mace EM, Hsu AP, Monaco-Shawver L, et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 2013, 121:2669-2677.
111. Calvo KR, Vinh DC, Maric I, et al. Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica 2011, 96:1221-1225.
112. Poulin S, Corbeil C, Nguyen M, et al. Fatal Mycobacterium colombiense/cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report. BMC Infect Dis 2013, 13:24.
113. Tang BS, Chan JF, Chen M, et al. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against γ interferon. Clin Vaccine Immunol 2010, 17:1132-1138.
114. Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, Browne SK Determination of human anticytokine autoantibody profiles using a particle-based approach. J Clin Immunol 2012, 32:238-245.
115. Browne SK, Zaman R, Sampaio EP, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood 2012, 119:3933-3939.
116. Patel SY, Ding L, Brown MR, et al. Anti-IFN-γautoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005, 175:4769-4776.
117. Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J Clin Invest 2005, 115:2480-2488.
118. Rosenzweig SD, Holland SM Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 2004, 113:620-626.
119. Wahn V Primary immunodeficiencies-the role of the laboratory. Clin Biochem 2011, 44:493-494.
120. Olivier KN, Weber DJ, Wallace RJ, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834.
121. Melia E, Freeman AF, Shea YR, Hsu AP, Holland SM, Olivier KN Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome. J Allergy Clin Immunol 2009, 124:617-618.
122. Rosenzweig DY Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979, 75:115-119.
123. Aksamit TR Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002, 23:643-653.
124. Sexton P, Harrison AC Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008, 31:1322-1333.
125. Chan ED, Iseman MD Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med 2013, 34:110-123.
126. Ratjen F, Doring G Cystic fibrosis. Lancet 2003, 361:681-689.
127. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013, 188:913-922.
128. Esther CR, Esserman DA, Gilligan P, Kerr A, Noone PG Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010, 9:117-123.
129. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003, 9:1587-1591.
130. Roux AL, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009, 47:4124-4128.
131. Paugam A, Baixench MT, Demazes-Dufeu N, et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010, 48(suppl 1):S32. SS6.
132. Horani A, Ferkol TW, Shoseyov D, et al. LRRC6 mutation causes primary ciliary dyskinesia with dynein arm defects. PloS One 2013, 8:e59436.
133. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004, 169:459-467.
134. Leigh MW, Zariwala MA, Knowles MR Primary ciliary dyskinesia: improving the diagnostic approach. Curr Opin Pediatr 2009, 21:320-325.
135. Knowles MR, Ostrowski LE, Leigh MW, et al. Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. Am J Respir Crit Care Med 2014, 189:707-717.
136. Djakow J, Svobodova T, Hrach K, Uhlik J, Cinek O, Pohunek P Effectiveness of sequencing selected exons of DNAH5 and DNAI1 in diagnosis of primary ciliary dyskinesia. Pediatr Pulmonol 2012, 47:864-875.
137. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008, 178:1066-1074.
138. Kartalija M, Ovrutsky AR, Bryan CL, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013, 187:197-205.
139. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989, 321:863-868.
140. Hollings NP, Wells AU, Wilson R, Hansell DM Comparative appearances of non-tuberculous mycobacteria species: a CT study. Eur Radiol 2002, 12:2211-2217.
141. Weiss CH, Glassroth J Pulmonary disease caused by nontuberculous mycobacteria. Expert Rev Respir Med 2012, 6:597-612.
142. Wittram C, Weisbrod GL Mycobacterium avium complex lung disease in immunocompetent patients: radiography-CT correlation. Br J Radiol 2002, 75:340-344.
143. Ziedalski TM, Kao PN, Henig NR, Jacobs SS, Ruoss SJ Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006, 130:995-1002.
144. Colombo RE, Hill SC, Claypool RJ, Holland SM, Olivier KN Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2010, 137:629-634.
145. Fowler CJ, Olivier KN, Leung JM, et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med 2013, 187:1374-1381.
146. Kartalija M, Ovrutsky AR, Bryan CL, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med 2013, 187:197-205.
147. Hallstrand TS, Ochs HD, Zhu Q, Liles WC Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency. Eur Respir J 2004, 24:367-370.
148. Greinert U, Schlaak M, Rusch-Gerdes S, Flad HD, Ernst M Low in vitro production of interferon-γ and tumor necrosis factor-α in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria. J Clin Immunol 2000, 20:445-452.
149. Kwon YS, Kim EJ, Lee SH, et al. Decreased cytokine production in patients with nontuberculous mycobacterial lung disease. Lung 2007, 185:337-341.
150. Safdar A, White DA, Stover D, Armstrong D, Murray HW Profound interferon γ deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med 2002, 113:756-759.
151. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008, 178:1066-1074.
152. Lim A, Allison C, Price P, Waterer G Susceptibility to pulmonary disease due to Mycobacterium avium-intracellulare complex may reflect low IL-17 and high IL-10 responses rather than Th1 deficiency. Clin Immunol 2010, 137:296-302.
153. Vankayalapati R, Wizel B, Samten B, et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J Infect Dis 2001, 183:478-484.
154. Safdar A, Armstrong D, Murray HW A novel defect in interferon-γ secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med 2003, 138:521.
155. Szymanski EP, Leung JM, Fowler CJ, et al. Pulmonary nontuberculous mycobacterial Infection: a multisystem multigenic disease. Am J Respir Crit Care Med (in press).
156. Yong PF, Freeman AF, Engelhardt KR, Holland S, Puck JM, Grimbacher B An update on the hyper-IgE syndromes. Arthritis Res Ther 2012, 14:228.
157. Guide SV, Holland SM Host susceptibility factors in mycobacterial infection. Genetics and body morphotype. Infect Dis Clin North Am 2002, 16:163-186.
158. Wallis RS, Broder M, Wong J, Beenhouwer D Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004, 39:1254-1255.
159. Algood HM, Lin PL, Flynn JL Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005, 41(suppl 3):S189-S193.
160. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
161. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013, 72:37-42.
162. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA Nontuberculous mycobacteria infections and anti-tumor necrosis factor-α therapy. Emerg Infect Dis 2009, 15:1556-1561.
163. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008, 46:1738-1740.
164. Serour F, Mizrahi A, Somekh E, et al. Analysis of the interleukin-12/interferon-γ pathway in children with non-tuberculous mycobacterial cervical lymphadenitis. Eur J Pediatr 2007, 166:835-841.
165. Remus N, Reichenbach J, Picard C, et al. Impaired interferon γ-mediated immunity and susceptibility to mycobacterial infection in childhood. Pediatr Res 2001, 50:8-13.
166. Olivier KN The natural history of nontuberculous mycobacteria in patients with cystic fibrosis. Paediatr Respir Rev 2004, 5(suppl A):S213-S216.
167. Esther CR, Henry MM, Molina PL, Leigh MW Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005, 40:39-44.
168. Freeman AF, Olivier KN, Rubio TT, et al. Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children. Pediatr Pulmonol 2009, 44:1051-1056.
169. Nolt D, Michaels MG, Wald ER Intrathoracic disease from nontuberculous mycobacteria in children: two cases and a review of the literature. Pediatrics 2003, 112:e434.